NCT00083005View on ClinicalTrials.gov

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Prostate Cancer

Interventions

DRUG

docetaxel

DRUG

estramustine phosphate sodium

DRUG

thalidomide

Trial Locations (2)

20892

NCI - Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00083005 - Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate | Biotech Hunter | Biotech Hunter